Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Jaguar Health, Inc.

Get SEC filing alerts via email and in your feed for Jaguar Health, Inc.

JAGX

Jaguar Health, Inc.

About Jaguar Health, Inc.

Jaguar Health, Inc. develops plant-derived prescription medicines targeting gastrointestinal disorders in humans and animals. Its core products include crofelemer-based drugs like Mytesi for HIV-related diarrhea and Canalevia for canine diarrhea. The company focuses on unmet medical needs such as cancer therapy-related diarrhea, rare diseases, and supportive care, leveraging sustainable botanical sources and proprietary formulations to provide first-in-class, natural treatment options globally.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from Jaguar Health, Inc.

1
1
Jaguar Health, Inc. Jaguar Health Reports $20.3M Revenue and $8.7M Net Income in Latest Quarter

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
Jaguar Health, Inc. Jaguar Health Reports $11.51M Revenue and $54M Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Jaguar Health, Inc. Jaguar Health Reports $30.8 Million Net Loss in Q3 2025, Revenue Increases Slightly

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Jaguar Health, Inc. Jaguar Health Reports $10.6 Million Net Loss in Q2 2025, Revenue Increases to $2.98 Million

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Jaguar Health, Inc. Jaguar Health Reports $10.6 Million Net Loss in Q1 2025, Revenue Declines 5.8%

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Jaguar Health, Inc. Jaguar Health Reports $39.25 Million Net Loss and 19.8% Revenue Increase for 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Jaguar Health, Inc. Jaguar Health Reports 10.5% Revenue Growth, Improved Financial Health in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments